Johnson & Johnson and AbbVie both exceeded Q1 2026 revenue expectations, prompting them to raise their full-year guidance. JNJ's growth was driven by diversified pharma and MedTech segments, notably TREMFYA and cardiovascular products, while AbbVie relied heavily on immunology drugs like Skyrizi and Rinvoq to offset biosimilar competition. Both companies face challenges from biosimilars but are pursuing different strategies: JNJ focuses on diversification and cell therapy investments, whereas AbbVie expands into obesity treatments. Investors see JNJ as a stable, dividend-paying giant and AbbVie as a growth-oriented specialist with promising pipeline catalysts ahead.
California retirees with dividend portfolios face significant state taxes that reduce their net income by about 23%, compared to states like Florida where the tax burden is much lower. Dividend yields vary by investment strategy: conservative portfol...
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
The FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) uses covered calls on Dividend Aristocrats stocks to deliver an 8.6% yield, appealing to retirees seeking income. However, this strategy caps upside gains, causing KNG to underperform t...
Vanguard Dividend Appreciation ETF (VIG) is often overlooked due to its low current yield of about 1.6%, but it focuses on companies with a strong history of dividend growth rather than high initial payouts. The fund tracks the S&P U.S. Dividend Grow...
Replacing a $65,000 annual salary with dividends requires a portfolio yield strategy. At a conservative 3% yield, you'd need about $2.17 million, but at an aggressive 10% yield, $650,000 suffices. Conservative stocks like Coca-Cola offer stability bu...
